USP7S-dependent inactivation of Mule regulates DNA damage signalling and repair

Svetlana V. Khoronenkova and Grigory L. Dianov*

Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK

Received October 3, 2012; Revised December 5, 2012; Accepted December 6, 2012

ABSTRACT

The E3 ubiquitin ligase Mule/ARF-BP1 plays an important role in the cellular DNA damage response by controlling base excision repair and p53 protein levels. However, how the activity of Mule is regulated in response to DNA damage is currently unknown. Here, we report that the Ser18-containing isoform of the USP7 deubiquitylation enzyme (USP7S) controls Mule stability by preventing its self-ubiquitylation and subsequent proteasomal degradation. We find that in response to DNA damage, downregulation of USP7S leads to self-ubiquitylation and proteasomal degradation of Mule, which eventually leads to p53 accumulation. Cells that are unable to downregulate Mule show reduced ability to upregulate p53 levels in response to DNA damage. We also find that, as Mule inactivation is required for stabilization of base excision repair enzymes, the failure of cells to downregulate Mule after DNA damage results in deficient DNA repair. Our data describe a novel mechanism by which Mule is regulated in response to DNA damage and coordinates cellular DNA damage responses and DNA repair.

INTRODUCTION

The p53 tumour suppressor protein plays a major role in the cellular DNA damage response by initiating either a cell cycle delay, to allow the completion of DNA repair processes before DNA replication, or by inducing apoptotic cell death in the case of excessive DNA damage that cannot be repaired (1,2). Although Mdm2 is widely accepted to be the major E3 ubiquitin ligase involved in the regulation of p53 levels (3,4), other E3 ubiquitin ligases, such as Mule (5), COP1 (6), and Pirh2 (7), have been shown to regulate the stability and activity of p53 in vitro and in living cells. However, their specific role in the cellular DNA damage response is unclear.

Among these E3 ubiquitin ligases, Mule (also known as ARF-BP1, E3Histone, UREB1, HUWE1, HECTH9 and LASU1) has recently attracted a significant amount of attention, as it was discovered to play multiple roles at the various stages of the cellular responses to DNA damage. Mule has been shown to play a key role in the tuning of the capacity of the base excision repair system, and, consequently, its ability to respond to oxidative DNA damage, by regulating the cellular levels of DNA polymerase β (8) and DNA polymerase λ (9). Other substrates of Mule, involved in multiple cellular processes, such as cell proliferation, apoptosis and DNA repair, have also been identified (for review see (10)). Importantly, it has been demonstrated that Mule ubiquitylates p53 protein directly, as depletion of Mule using siRNA results in a significant increase in the cellular levels of p53 (11). Taken together, these data indicate that p53 suppression in unstressed cells is one of the major functions of Mule. Therefore, in response to DNA damage, the p53-suppression function of Mule should be downregulated to enable the cellular DNA damage response. Indeed, Mule is inhibited by the ARF tumour suppressor protein that is induced by oncogenic stress (5,8). However, ARF-deficient cells are still able to elevate p53 levels in response to DNA damage (12), suggesting the existence of an ARF-independent pathway for Mule downregulation in response to DNA damage.

We have recently identified an important role for a specific isoform of USP7 that is phosphorylated at serine 18 residue (further referred to as USP7S) in regulation of p53 levels in response to DNA damage (13). As it was previously shown that Mule may potentially interact with USP7S (14), we decided to investigate the role of USP7S in the regulation of Mule. Here, we report that USP7S controls the cellular levels of Mule in response to DNA damage, and it regulates the efficiency of DNA repair.

*To whom correspondence should be addressed. Tel: +44 1865 617325; Fax: +44 1865 617334; Email: grigory.dianov@oncology.ox.ac.uk

© The Author(s) 2012. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
MATERIALS AND METHODS

Antibodies, proteins, plasmids, chemicals and cell lines
Polyclonal pUSP7S and USP7S antibodies were produced by Biomatik as described in (13). Actin (ab6276), ubiquitin (ab7254) and HA (ab9110) antibodies were purchased from Abcam, Flag antibodies (200471) were from Agilent Technologies, p53 (sc-126) antibodies were from Santa Cruz, Mule antibodies used for in vivo studies were from Bethyl Laboratories (UREB1, BET-A300-486A) and ProSci (4213), respectively, Pol λ antibodies (A301-640A) were from Bethyl Laboratories and PPM1G antibodies were kindly provided by O. Gruss. Pol β antibodies were produced as described in (15).

Ubiquitin, E1 and E2 enzymes were purchased from Boston Biochemicals. Mammalian expression vectors encoding the usp7s wild-type as well as usp7s/C223S mutant genes and production and purification of the corresponding proteins were as described in (13). Bacterial and mammalian expression vectors encoding Mule HECT-domain were kindly provided by Dr M. Eilers. The GST-tagged truncated Mule protein was expressed in Escherichia coli cells and purified using GSTrap FF column chromatography (GE Healthcare).

HeLa (adenocarcinoma) and HCT116p53+/+(colorectal carcinoma) cell lines were purchased from ATCC.

Whole-cell extracts
Whole-cell extracts were prepared as described in (8).

RNA interference

Cells were transfected using Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer’s protocol. The siRNA sequences used to target the Mule, PPM1G and Mdm2 transcripts were as follows: 5'-AAUU GCUAUGUCUCUGGACA-3' (5), 5'-AGGCUACCA UGACUAUUGA-3' (16) and 5'-AAGCCAUGCUU UGAAGUA-3' (17), respectively. To knockdown Ser18-containing USP7 isoform (USP7S), the 5'-AGCG GGCAGCAGCAGAGG-3' sequence was used (13). The GFP siRNA sequence (5'-GCUGACCCUGAAUU UCAUCU-3') served as a control.

DNA damaging treatments

Cells were subjected to ionizing radiation using GSR-D1 137Cs γ-iradiator (RPS Services Limited) at a dose rate of 1.8 Gy/min (8-Gy dose). For hydrogen peroxide and etoposide treatments, cells were treated with either 150 μM H2O2 for 15 min or 10 μM etoposide dissolved in DMSO for 1 h. The medium was changed after the treatment, and cells were incubated at 37°C to allow for DNA repair. The Comet assay was performed as described in (8).

In vitro ubiquitylation and deubiquitylation assays

Mule (25 pmol) was self-ubiquitylated in the presence of 7 pmol E1, 65 pmol UbcH7 and 6 pmol ubiquitin in buffer containing 25 mM Tris–HCl, pH 8.0, 4 mM adenosine triphosphate, 5 mM MgCl2, 200 μM CuCl2, 1 mM DTT and 10 μM MG-132 for 1 h at 30°C with shaking. Ubiquitin and E2 were removed from the reaction mixture by filtration and buffer exchange into deubiquitylation buffer containing 50 mM Tris–HCl, pH 8.0, 150 mM KCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 5% glycerol and 2 mM DTT using Amicon Ultra 30 K units (Millipore). For the deubiquitylation assay, ubiquitylated Mule (0.6 pmol) was incubated with equal amounts of wild-type USP7S or inactive C223S USP7S mutant (1.2 and 2.4 pmol) in deubiquitylation buffer for 30 min at 30°C with shaking. To stop the reaction, sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) sample buffer (25 mM Tris–HCl, pH 6.8, 2.5% β-mercaptoethanol, 1% SDS, 5% glycerol, 1 mM EDTA and 0.05 mg/ml bromophenol blue) was added to samples, which were then heated for 5 min at 95°C before separation of the proteins on a 4–20% SDS–PAGE gel, followed by transfer to a PVDF membrane and western blotting with Ubi, Mule and USP7S antibodies.

Western blots

Western blots were performed by standard procedure as recommended by the vendor (Novex). Blots were visualized and quantified using the Odyssey image analysis system (Li-Cor Biosciences). For quantification (below the appropriate figure), the expression levels of proteins were normalized against the actin loading control as calculated from at least three independent experiments.

Real-time polymerase chain reaction

Real-time polymerase chain reaction was performed as described in (13), using the 5'-TGAAATGCTCTGGCTG CATAC-3' and 5'-CCCCAGGTTTTAGGATCATTAC-3' primers for amplification of the Mule transcript. The results are presented as a mean ± standard deviation of three independent biological experiments. Statistical analysis was performed using Student’s paired t-test with a two-tailed distribution.

RESULTS AND DISCUSSION

USP7S interacts with Mule and prevents its self-ubiquitylation

To address the role of USP7S in the regulation of Mule protein levels, we firstly followed up the proteomic studies by the Harper laboratory (14) that suggested an interaction of Mule with USP7S and demonstrated that catalytically active Mule HECT-domain efficiently interacts with USP7S, both in vitro (Figure 1A) and in vivo (Figure 1B). As with many other E3 ubiquitin ligases, Mule is self-ubiquitylated when incubated in the presence of ubiquitin ([5]; Figure 1C, first lane). In a cellular environment, such self-ubiquitylation can result in proteasomal degradation of the protein, although this may be prevented by deubiquitylation. Therefore, we analysed whether USP7S can limit Mule
self-ubiquitylation through its associated deubiquitylation activity. Indeed, using self-ubiquitylated Mule as a substrate, we demonstrated that USP7S, but not its catalytically inactive mutant (C223S), efficiently deubiquitylates Mule in an in vitro reaction reconstituted with the recombinant proteins (Figure 1C).

**USP7S controls the cellular levels of Mule**

Having established that Mule and USP7S form a complex and that USP7S deubiquitylates self-ubiquitylated Mule in vitro, we questioned whether USP7S also controls Mule protein levels in living cells. To answer this question, we suppressed the expression of USP7S in HeLa cells using siRNA and found decreased levels of Mule (Figure 2A). To further prove that downregulation of Mule protein levels after USP7S knockdown is because of a reduced amount of USP7S, rather than an indirect effect of the siRNA, we first depleted USP7S and then transfected these cells with a plasmid encoding siRNA resistant USP7S mRNA and observed a complete restoration of Mule protein levels (Figure 2B). Interestingly, overexpression of USP7S in HeLa cells did not affect the cellular levels of Mule (Figure 2C), suggesting that there is a cellular excess of the USP7S deubiquitylating activity that ensures relatively high stability of Mule,
which consequently suppresses the levels of the p53 tumour suppressor under unstressed conditions.

To prove that reduced Mule protein levels in USP7S-depleted cells were a result of its protein degradation, rather than downregulation of mule gene transcription, we measured Mule mRNA levels in USP7S-knockdown HeLa cells. Indeed, we detected an increased, rather than a decreased, level of mule mRNA in these cells compared with control cells (Figure 2D). An elevation of mule mRNA levels involves, most probably, a compensatory mechanism that is intended to restore cellular Mule protein levels, so that the steady-state equilibrium of the E3 ubiquitin ligase, and its substrates, can be maintained. Having proved that the regulation of cellular Mule levels by USP7S occurs at a protein level, we further aimed to demonstrate that this downregulation is accomplished through proteasomal degradation. To this end, after a USP7S knockdown that leads to reduction in Mule cellular protein levels (Figure 2E, lane 2), we treated cells with the proteasome inhibitor MG-132 and were able to restore Mule protein levels (Figure 2E, lane 3). Thus, we concluded that USP7S prevents Mule self-ubiquitylation and subsequent proteasomal degradation.

**Downregulation of Mule in response to DNA damage is controlled by USP7S**

Taken together, our data suggest that the steady-state protein levels of Mule are tightly regulated by USP7S-dependent deubiquitylation that balances Mule self-ubiquitylation; therefore, it is controlled mainly by the activity of the USP7S protein. We have recently demonstrated that under acute DNA damage stress, USP7S is downregulated at the early stages of the cellular DNA damage response (13). As we have linked the cellular steady-state protein levels of Mule to the level and activity of USP7S protein, we hypothesized that Mule may also be downregulated during the early stages of the DNA damage response. Indeed, when we monitored the effect of various DNA damaging agents on Mule protein levels, we found that within 15–60 min after treatment with hydrogen peroxide (Figure 3A), etoposide (Figure 3B) or ionizing radiation (Figure 3C), both pUSP7S and Mule were simultaneously reduced. This was followed by a restoration in their protein levels at later time points post-treatment and highlights a direct correlation between the protein levels of USP7S and Mule. As we previously demonstrated that proteasomal degradation of USP7S in response to DNA damage is triggered by its dephosphorylation by the ATM-dependent phosphatase PPM1G (13), we prompted to analyse whether deregulation of Mule protein levels in response to DNA damage is also dependent on PPM1G activity. To this end, we treated PPM1G siRNA-depleted HCT116p53+/+ cells with etoposide and observed that there was no decrease in Mule, as well as pUSP7S protein levels, in response to DNA damage in cells lacking PPM1G in comparison with control-treated cells (Figure 3D). This suggests that PPM1G is required for downregulation of Mule protein levels, in response to DNA damage.

---

**Figure 3.** Mule is downregulated after DNA damage, and this is controlled by USP7S. (A–C) HCT116 p53+/+ cells were either left untreated (Contr) or exposed to (A) 150 μM hydrogen peroxide for 15 min, (B) 10 μM etoposide (Eto) for 1 h or (C) 8-Gy ionizing radiation (IR) and harvested at the indicated time points post-treatment. (D) HCT116 p53+/+ cells were transfected with PPM1G siRNA (200 pmol) for 72 h, cells were then harvested either without any additional treatment (+) or 1 h post-treatment with etoposide (+) as previously described. Whole-cell extracts were prepared, proteins were separated by 4–20% SDS-PAGE and analysed by western blotting using the indicated antibodies.

**Downregulation of Mule after DNA damage is required for efficient DNA repair and p53 upregulation**

It was earlier demonstrated that a Mule knockdown, in a similar way as an Mdm2 knockdown, stabilizes p53 and, therefore, reduces the rate of cell proliferation and induces p53-dependent apoptosis (5,11). We now demonstrate that treatment of cells with a variety of DNA damaging agents...
results in a substantial reduction of cellular levels of Mule (Figure 3). We further demonstrate that both downregulation of Mule by siRNA or in response to ionizing radiation results in elevated levels of the cellular p53 protein (Figure 4A). We, therefore, hypothesized that downregulation of Mule in response to DNA damage is required for the p53 response to be activated. In support of this hypothesis, we found that overexpression of Mule reduces the upregulation of p53 in response to ionizing radiation (Figure 4B, compare lanes 2 and 4; Figure 4C). It should be noted that, as the p53 regulation in response to DNA damage is accomplished via multiple pathways, the restriction of p53 upregulation by DNA damage imposed by Mule overexpression is partially rescued through other mechanisms. Most probably this happens via downregulation of Mdm2, which is also accomplished through the same ATM–PPM1G–USP7S pathway that controls Mule levels (13).

Mule also controls a number of proteins involved in the cellular DNA damage response that are not regulated by Mdm2, in particular DNA polymerases β and λ (8,9), which are important players in base excision repair. Indeed, we have previously demonstrated that inactivation of Mule results in more efficient DNA repair (13). Correspondingly, if Mule downregulation in response to DNA damage is required for DNA repair, then overexpression of Mule should reduce the cellular capacity for DNA repair. In fact, we found that overexpression of Mule in HeLa cells results in a reduction of Pol β and Pol λ levels (Figure 4D), and a reduced rate

Figure 4. Mule downregulation after DNA damage is required to coordinate the p53 DNA damage response with DNA repair. (A) HCT116 p53+/+ cells were transfected with Mule-specific siRNA (200 pmol) for 72 h (left panel). Alternatively (right panel), cells were either left untreated (−) or exposed to 8-Gy ionizing radiation (+) and harvested 1 h post-treatment (IR). (B) HCT116 p53+/− cells were transfected with HA-tagged Mule expressing plasmid (1 pmol) for 24 h and then treated with IR as described in (A). (C) Graphical analysis of the data presented in (B). Statistical data are presented as a mean ± standard deviation, *P < 0.01 and **P < 0.001, as analyzed by Student's t-test. (A, B, D) Whole-cell extracts were prepared, proteins were separated by 4–20% SDS–PAGE and analysed by western blotting using the indicated antibodies.
of DNA repair as measured by the alkaline single-cell gel electrophoresis (comet) assay (Figure 4E).

In our previous work, we demonstrated that the regulation of Mdm2, and consequently p53 protein levels, is accomplished through the ATM–PPM1G–USP7S pathway (13). We now demonstrate that Mule is also downregulated in response to DNA damage via the same signalling pathway, and this downregulation is required for p53 accumulation and efficient DNA repair. As we have previously shown, in unstressed cells, the majority of USP7S is phosphorylated by the CK2 protein kinase, and thus is stabilized (13). This ensures stabilization of USP7S substrates, such as Mule and Mdm2, which mediate proteasomal degradation of p53 in unstressed cells. In response to DNA damage, the protein phosphatase PPM1G is activated by ATM that results in dephosphorylation, and therefore destabilization, of USP7S. This, in turn, leads to DNA damage-dependent downregulation of both Mdm2 (13) and Mule, as we demonstrated in this study (Figure 5).

Therefore, we propose that the cellular levels of p53 are regulated by Mule and Mdm2 via the same DNA damage signalling pathway that involves ATM, PPM1G and USP7S as the upstream regulators. In addition to the common function of p53 regulation, Mule and Mdm2 E3 ubiquitin ligases control a number of distinct proteins such as Pol β, Pol λ and forkhead homeobox type O transcription factors that orchestrate different aspects of the cellular response to DNA damage (Figure 5).

Our findings provide the mechanism of how DNA damage is reported to Mule, which consequently contributes to activation of the p53-dependent DNA damage response, as well as allowing for DNA repair to be accomplished within a required time frame through the regulation of the levels of DNA Pol β and Pol λ. Additionally, it should be noted that Mule has been shown to be overexpressed in a high percentage of tumour cell lines (18,19). As we demonstrated (Figure 4B and C), elevated levels of Mule may attenuate, at least partially, the upregulation of the p53 protein in response to DNA damage and inhibit prompt DNA repair via the base excision repair pathway; therefore, it may possibly be one of the major reasons for genetic instability in these cancer cells.

ACKNOWLEDGEMENTS

The authors thank Dr Jason Parsons for critically reading the manuscript and Dr Irina Dianova for technical help.

FUNDING

Medical Research Council and Cancer Research UK (to G.L.D.); Oxford Cancer Research Centre Development Fund (to S.V.K.). Funding for open access charge: Medical Research Council and Cancer Research UK.

Conflict of interest statement. None declared.

REFERENCES

1. Vogelstein,B., Lane,D. and Levine,A.J. (2000) Surfing the p53 network. Nature, 408, 307–310.
2. Levine,A.J. and Oren,M. (2009) The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer., 9, 749–758.
3. de Rozieres,S., Maya,R., Oren,M. and Lozano,G. (2000) The loss of mdm2 induces p53-mediated apoptosis. Oncogene, 19, 1691–1697.
4. Vousden,K.H. and Prives,C. (2009) Blinded by the light: the growing complexity of p53. Cell, 137, 413–431.
5. Chen,D., Kon,N., Li,M., Zhang,W., Qin,J. and Gu,W. (2005) ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell, 121, 1071–1083.
6. Leng,R.P., Lin,Y., Ma,W., Wu,H., Lemmers,B., Chung,S., Parant,J.M., Lozano,G., Hakem,R. and Benchimol,L. (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell, 112, 779–791.
7. Dornan,D., Wertz,I., Shimizu,H., Arnott,D., Frantz,G.D., Dowd,P., O’Rourke,K., Koeppe,H. and Dixit,V.M. (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature, 429, 86–92.
8. Parsons,J.L., Tait,P.S., Finch,D., Dianova,I.I., Edelmann,M.J., Khoronenkova,S.V., Kessler,B.M., Sharma,R.A., McKenna,W.G. and Dianov,G.L. (2009) Ubiquitin ligase ARF-BP1/Mule modulates base excision repair. EMBO J., 28, 3207–3215.
9. Markkanen,E., van Loon,B., Ferrari,E., Parsons,J.L., Dianov,G.L. and Hubscher,U. (2012) Regulation of oxidative DNA repair damage by RNA polymerase lambda and MutYH by cross-talk of phosphorylation and ubiquitination. Proc. Natl. Acad. Sci. USA, 109, 437–442.
10. Khoronenkova,S.V. and Dianov,G.L. (2011) The emerging role of Mule and ARF in the regulation of base excision repair. FEBS Lett., 585, 2831–2835.
11. Kon,N., Zhong,J., Qiang,L., Accili,D. and Gu,W. (2012) Inactivation of arf-bp1 induces p53 activation and diabetic phenotypes in mice. J. Biol. Chem., 287, 5102–5111.
12. Kamijo,T., van de Kamp,E., Chong,M.J., Zindy,F., Diehl,J.A., Sherr,C.J. and McKinnon,P.J. (1999) Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res., 59, 2464–2469.
13. Khoronenkova, S.V., Dianova, I.I., Ternette, N., Kessler, B.M., Parsons, J.L. and Dianov, G.L. (2012) ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage. Mol. Cell., 45, 801–813.

14. Sowa, M.E., Bennett, E.J., Gygi, S.P. and Harper, J.W. (2009) Defining the human deubiquitinating enzyme interaction landscape. Cell, 138, 389–403.

15. Dianova, I.I., Bohr, V.A. and Dianov, G.L. (2001) Interaction of human AP endonuclease 1 with flap endonuclease 1 and proliferating cell nuclear antigen involved in long-patch base excision repair. Biochemistry, 40, 12639–12644.

16. Petri, S., Grimmler, M., Over, S., Fischer, U. and Gruss, O.J. (2007) Dephosphorylation of survival motor neurons (SMN) by PPM1G/PP2Cgamma governs Cajal body localization and stability of the SMN complex. J. Cell. Biol., 179, 451–465.

17. Jin, Y., Lee, H., Zeng, S.X., Dai, M.S. and Lu, H. (2003) MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J., 22, 6365–6377.

18. Adhikary, S., Marinoni, F., Hock, A., Hulleman, E., Popov, N., Beier, R., Bernard, S., Quarto, M., Capra, M., Goettig, S. et al. (2005) The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell, 123, 409–421.

19. Yoon, S.Y., Lee, Y., Kim, J.H., Chung, A.S., Joo, J.H., Kim, C.N., Kim, N.S., Choe, I.S. and Kim, J.W. (2005) Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein. Biochem. Biophys. Res. Commun., 326, 7–17.